Eligible patients screened for CFRD | ||||
---|---|---|---|---|
National (n) screening rate | MWCFC (n) screening rate | OR* | 95% CI* | |
2002 | 1305 (19 680) 6.6% | 125 (1243†) 10% | 1.79 | 1.49 to 2.13 |
2004 | 1527 (18 807) 8.1%‡ | 185 (1226†) 15%‡ | 1.81 | 1.54 to 2.14 |
OR* | 1.41 | 1.71 | ||
95% CI* | 1.38 to 1.45 | 1.57 to 1.85 |
*ORs calculated using generalized linear models (logistic regression) with screening by FBG alone or OGTT as the dependent variable. The 95% CIs all indicate a significance level of p<0.001.
†The n's and screenings reported for MWCFC care centers for 2002 and 2004 differ from those reported in table 1. More patients were screened and fewer were eligible for the study compared with patients included in the CFFPR. The differences are due to the exemption from consent for measuring center adherence to screening guidelines within the QI study compared with required consent for inclusion in the CFFPR, differences in determination of primary care center (and thus study participation eligibility) by the local centers versus the CFFPR and the option afforded to CFFPR patients to withdraw consent with retroactive data erasure at any time. Differences in patients included in the CFFPR compared with the MWCFC study account for the statistically significant improvement in CFRD screening that was not captured in the current study.
‡By 2011, screening rates utilizing either FBG alone or OGTT had risen to 23% nationally and 29% in the original MWCFC centers, maintaining an OR of 1.26 (95% CI 1.12 to 1.41, p<0.001) for screening in the MWCFC compared with the rest of US centers.
CF, cystic fibrosis; CFRD, CF-related diabetes; CFFPR, CF Foundation Patient Registry; FBG, fasting blood glucose; MWCFC, Mountain West CF Consortium; OGTT, oral glucose tolerance test; QI, quality improvement.